Highest-materiality recent filing
Elanco shareholders elect all director nominees, ratify EY, approve say-on-pay at annual meeting
All five director nominees elected; highest support for Lawrence Kurzius (443M for).
Elanco Q1 revenue +15% to $1.37B, raises FY2026 guidance across all metrics
Q1 revenue $1.37B (+15% reported, +10% organic constant currency); adjusted EPS $0.40 vs $0.37 prior year.
Q4 2025 revenue $1,144M (+12% reported, +9% organic CC); reported net loss $276M, adjusted EPS $0.13.
Elanco to present at J.P. Morgan Healthcare Conference; no new material information disclosed
Presentation reiterates innovation, portfolio, productivity strategy, pipeline, financial outlook, and executive team insights from December Investor Day.
Restructuring: ~300 jobs eliminated, ~300 shifted; ~$175M pretax charge (~$130M cash); closure of Kansas City implant facility, partial exit from Monheim Germany.
Elanco Q3 revenue $1.14B (+10% YoY); raises FY guidance, net leverage improves
Q3 revenue $1,137M (+10% reported, +9% organic CC); adjusted EPS $0.19 vs $0.13 YoY (+46%).
Elanco refinances $1.1B + €400M + $540M credit facilities; extends maturities
Amendment No. 3 to Credit Agreement signed Oct 31, 2025; refinances existing term loans.
Elanco Q2 rev +5% to $1.24B, raises FY2025 outlook; net leverage target improved
Q2 revenue $1,241M (+5% reported, +8% organic CC); adjusted EPS $0.26 vs $0.30 prior year.
Elanco extends receivables securitization facility to June 2028
Term extended from August 3, 2026 to June 26, 2028 via First Amendment to Receivables Loan Agreement.
Elanco appoints Robert VanHimbergen as CFO effective July 7, 2025
Robert VanHimbergen appointed EVP and CFO, effective July 7, 2025; Todd Young stays as advisor through Aug 31, 2025.
Elanco annual meeting results: directors elected, say-on-pay approved with 46.5% dissent
Directors Kapila K. Anand and Paul Herendeen elected; Anand faced 156M votes against (34%).
Elanco Q1 beats; FY25 revenue raised to $4.51-4.58B; debt paydown accelerated
Q1 revenue $1,193M (-1% reported, +4% organic CC); adj EPS $0.37 vs $0.34 YoY, above guidance.
Board to shrink to 11 directors; Bilbrey, Turner, Wallace won't stand for re-election; Doyle resigned.
Elanco Q4 adjusted EPS $0.14, revenue $1.02B; FY 2025 guidance reflects FX headwinds
Q4 2024 revenue $1,020M (-1% reported, +4% organic CC); adjusted EPS $0.14 (vs $0.08); adjusted EBITDA $177M (17.4% margin).
CEO Jeff Simmons will present at the 43rd Annual J.P. Morgan Healthcare Conference.
Elanco appoints Stacey Ma to board; board expands to 15 members
Ma appointed effective Nov 11, 2024; board increased from 14 to 15 directors.
Elanco Q3 revenue $1.03B, +1% organic; adj. EPS $0.13; 2024 guidance tightened
Reported net income $364M ($0.73 EPS) includes $640M pre-tax gain from July aqua divestiture; adjusted net income $66M ($0.13 EPS).
Elanco presents Zenrelia study showing similar serologic response; approved in Canada
Study presented at ISCAID: 68 beagles given ilunocitinib at 1X or 3X label dose for 56 days; protective titer levels post-booster similar to control group.
Elanco enters $350M incremental term loan facility due 2031 to repay existing debt
New incremental term facility of $350M, matures on August 13, 2031.
Elanco Q2 revenue $1.184B, adjusted EPS $0.30; raises full-year revenue guidance
Q2 revenue $1.184B (+12% reported, +13% CC); pet health $579M (+12%), farm animal $594M (+13%).
Elanco completes sale of aqua business to Merck for ~$1.3B; debt reduction plan outlined
Sale to Merck closed July 9 for ~$1.3B cash; net proceeds ~$1.05-1.1B for Q3 debt paydown.
Elanco extends revolver maturity to 2029, enhancing liquidity
Extended revolving credit facility maturity from Aug 1, 2025 to July 3, 2029.
Elanco shareholders approve board declassification, majority voting, and special meeting rights
Board declassified, majority vote standard adopted for uncontested director elections.
Q1 revenue $1.205B (-4% reported/CC); reported EPS $0.06, adjusted EPS $0.34; adjusted EBITDA $294M (-22%).
Elanco appoints two directors, reaches cooperation agreement with Ancora
Appointed Kathy Turner and Craig Wallace to the Board effective March 29, 2024; Board size increased from 12 to 14.
Elanco reports Q4 net loss $141M, full-year loss $1.23B; cuts 420 jobs in restructuring
Q4 2023 revenue $1,035M (+5% YoY); reported net loss $141M ($0.29 EPS), adjusted EPS $0.08.
Elanco sells aqua business to Merck Animal Health for $1.3B cash
Transaction valued at approx. 7.4x estimated 2023 revenue of $175M and adjusted EBITDA of $92M.
Elanco files 8-K for J.P. Morgan conference presentation; no new financial data disclosed
Company to present at 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024.
Elanco names Lawrence Kurzius next Chairman; proposes board declassification and majority voting
Lawrence Kurzius to become Chairman after 2024 annual meeting; R. David Hoover remains on board.
Revenue $1,068M (+4% reported, +5% CC); Pet Health +6% CC, Farm Animal +4% CC.
Elanco to seek shareholder approval for board declassification and enhanced shareholder rights
Board to seek shareholder approval at 2024 annual meeting to declassify Board of Directors.
Elanco Q2 revenue $1,057M, adj EPS $0.18; raises full-year guidance
Revenue $1,057M (-10% YoY); estimated $90-$110M ERP blackout impact shifted Q2 revenue to Q1.
EPA completes Seresto review, confirms registration; Elanco implements stewardship program
EPA completed multi-year review of Seresto collar, confirms continued registration; safety profile affirmed.
On July 7, 2023, Elanco sent notice to redeem all outstanding Senior Notes due August 28, 2023.
Elanco shareholders elect two directors despite majority against; stock plans approved
Directors R. David Hoover and Deborah T. Kochevar elected with more against votes than for (125M vs 309M; 164M vs 269M) under plurality.
Elanco Q1 revenue $1.257B, adj EPS $0.45; raises low end of FY guidance
Q1 revenue $1,257M (+3% reported, +6% CC); includes estimated $90-110M benefit from ERP blackout.
Q4 2022 revenue revised down $3M to $985M; reported net loss increased to $55M; adjusted EBITDA $172M (down $2M).
Elanco Q4 revenue $988M (-11% YoY), full year net loss $74M; guides FY2023 revenue $4.28-4.4B
Q4 revenue $988M (-11% reported, -6% CER); Pet Health $423M (-14%), Farm Animal $552M (-9%).
Elanco announces settlement of Tangible Equity Units; will issue ~17.2M shares on Feb 1, 2023
On Feb 1, 2023, holders receive 1.5625 shares per prepaid stock purchase contract; cash in lieu of fractional shares.
Elanco discloses FDA submission for JAK inhibitor at JPM conference
Company notes Q4 2022 submission to FDA for its JAK inhibitor.
Elanco Q3 revenue $1,028M, net loss $49M; cuts FY 2022 guidance on FX and macro headwinds
Q3 revenue down 9% reported (4% constant currency) to $1,028M; pet health fell 11%, farm animal down 7%.
Scott Ferguson steps down from Elanco board to focus on other Sachem Head commitments
Scott Ferguson, founder of Sachem Head Capital Management, resigned from Elanco's board effective Sept 7, 2022.
Elanco Q2 revenue $1.177B down 8%; cuts full-year guidance on macro headwinds
Q2 revenue $1,177M (-8% reported, -4% constant currency); Pet Health $612M (-11%), Farm Animal $553M (-2%).
Elanco enters $175M incremental term facility, matures June 2025
$175M incremental term loan facility entered June 28, 2022; proceeds used to repay revolving facility borrowings.
Shareholders approved elimination of supermajority vote to remove directors, replaced with majority vote.
Elanco Q1 revenue $1.225B, adj. EPS $0.36; FY22 guidance lowered on FX headwind of $140M
Q1 revenue $1,225M (-1% reported, +2% CER); reported net income $48M vs -$61M; adjusted EPS $0.36 vs $0.37.
Elanco enters $250M incremental term loan facility maturing April 2029
New $250M incremental term facility under existing credit agreement; matures April 19, 2029.
Elanco spins out microbiome platform into BiomEdit with $40M funding; tenders $406M of 2023 notes
Elanco launches BiomEdit, a microbiome innovation company, with $40M Series A from Viking Global and Anterra Capital.
Elanco commences $250M tender offer for 4.272% 2023 notes
Commenced cash tender offer to purchase up to $250M principal of 4.272% Senior Notes due 2023.
Elanco FY21 rev $4,765M, adj EPS $1.05; Q4 adj EPS $0.21 (+75%); FY22 adj EPS guidance $1.18-1.24
Full year 2021 revenue $4,765M (+46% YoY); reported EPS -$0.97, adjusted EPS $1.05.
the Company announced the appointment of Robert (Bob) VanHimbergen as Executive Vice President and Chief Financial Officer, effective July 7, 2025.
Mr. VanHimbergen succeeds Todd Young who will continue to serve as an advisor, in a non-executive capacity, through August 31, 2025.
the Company announced certain changes to its Board of Directors, including the decision by William F. Doyle to resign from the Board, effective upon the Company entering into a research agreement
On November 11, 2024, the Board of Directors (the “Board”) of Elanco Animal Health Incorporated (the “Company”) appointed Stacey Ma, PhD, to the Board
On March 29, 2024, Ms. Turner and Mr. Wallace were appointed to the Board.
On March 29, 2024, Ms. Turner and Mr. Wallace were appointed to the Board.
Scott D. Ferguson, a member of the Board of Directors (the “Board”) of the Company and founder and managing partner of Sachem Head Capital Management (“Sachem Head”), an investor in the Company, has stepped down from the Board, effective September 7, 2022, in connection with Mr. Ferguson and Sachem Head refocusing his time across other Sachem Head Board commitments.
On December 31, 2021, Mr. Schacht, and certain other employees supporting the Microbiome Platform, separated from Elanco as part of the restructuring plan announced by Elanco on November 30, 2021.
Aaron Schacht, Elanco’s Executive Vice President of Innovation, Regulatory, and Business Development, is transitioning to lead the potential carve-out of Elanco’s microbiome R&D platform
Max materiality 0.85 · Median 0.60 · Most common event earnings